Bio Innovation Conference | Subhendu Basu Ph.D.
Presented by Maryland Life Sciences, a division of the Maryland Tech Council, the Bio Innovation Conference is driving the future of life sciences in Maryland. This conference provides a forum for professionals from industry, academia and government to discuss trends and insight into Maryland’s burgeoning life sciences industry and topics related to funding, structuring, commercialization and government relations.
Maryland Life Sciences Bio Innovation Conference, Bio Innovation Conference, Maryland, life sciences, biotechnology, Maryland Tech Council, bio, innovation, conference, Maryland Life Sciences, Bio Innovation Conference, vaccines, gene therapy, networking, Washington DC, DMV, Biohealth, biohealth capital region, sciences, entrepreneurship, entrepreneur, startup, Maryland Life Sciences Bio Innovation Conference, Maryland Tech Council Conference, annual conference
page-template-default,page,page-id-19741,page-child,parent-pageid-16863,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-17.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-5.6,vc_responsive

Subhendu Basu Ph.D.

Subhendu Basu Ph.D.

Chief Operating Officer, Adaptive Phage Therapeutics

Dr. Basu is COO at Adaptive Phage Therapeutics (APT), a company that is developing biological treatments to combat infectious diseases. APT’s novel and adaptive approach overcomes the Achilles heel of traditional ‘fixed’ methods of combating bacterial infections, that inevitably lead to the emergence of drug resistance –

Prior to joining APT, Dr. Basu headed Scientific Affairs at Emergent BioSolutions Inc. and oversaw technical diligence for all acquisition and in-licensing activities. During his tenure at Emergent, Dr. Basu was integral to M&A in excess of $1B that resulted in the addition of 10 marketed products and multiple pipeline assets, that included vaccines, therapeutics and drug-device combination products.

Subhendu received his PhD in Immunology and Pathology from the University of Maryland, School of Medicine and was Assistant Professor at the Center for Vaccine Development prior to transitioning to biopharma.